TrialCancer medicine2018

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Johan Lund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.